BDNF and Huntington disease: Of note, the PRIDE-HD phase II exploratory trial (NCT02006472) documented a delay in the reduction in total functional capacity in HD patients over one year of pridopidine treatment, but is not known if BDNF up-regulation was responsible for this outcome [243,244].